XNAS · LAB
-2.07% · -$0.0194 · Vol 1.3M
Market closed · last close 4:00 PM ET · price as of 16:01:34 ET
Standard BioTools Inc. Common Stock

Standard BioTools Inc. Common Stock

LABORATORY ANALYTICAL INSTRUMENTS
$0.9184
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
HISTORY WINDOW BUILDING
AI Analysis
Sovereign

Why is LAB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for LAB are being assembled.
About Standard BioTools Inc. Common Stock
LABORATORY ANALYTICAL INSTRUMENTS
Listed since
2011
Employees
389
Country
US

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.9378
Day high
$0.9661
Day low
$0.9027
Previous close
$0.9378
52W high
$0.9661
-4.94% from high
52W low
$0.9027
25% of range
Market cap
$367.1M
P/E
11.48×
EPS
$0.0800
Shares out
391.5M
Volume
1.3M
VWAP
$0.9293
Price history computed in-house
SMA 50 $0.9184 · above
SMA 200 $0.9184 · above
52W position 25%
Veridion warehouse edge

Warehouse intelligence for LAB.

Veridion Score
51
0: 861: 432: 513: 294: Not reported5: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

LAB insider activity

Standard BioTools Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for LAB.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

LAB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LAB in this window.
Lobbying spend

LAB lobbying filings, year to date.

Registered lobbying filings matched to Standard BioTools Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LAB in this window.
Latest news · LAB
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for LAB.
Options
Sovereign unlock shows live options positioning for LAB.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.